Membrane-type matrix metalloproteinases (MT-MMPs) have attracted strong attention, because four of them can activate a key player in the tumor scenario, proMMP-2/progelatinase A. In addition to this indirect effect on the cellular environment, these MT-MMPs degrade extracellular matrix proteins, and their overproduction is associated with tumor growth. We have solved the structure of the catalytic domain (cd) of MT3-MMP/MMP-16 in complex with the hydroxamic acid inhibitor batimastat. CdMT3-MMP exhibits a classical MMP-fold with similarity to MT1-MMP Nevertheless, it also shows unique properties such as a modified MT-specific loop and a closed S1' specificity pocket, which might help to design specific inhibitors. Some MT-MMP-specific features, derived from the crystal structures of MT-1-MMP determined previously and MT3-MMP, and revealed in recent mutagenesis experiments, explain the impaired interaction of the MT-MMPs with TIMP-1. Docking experiments with proMMP-2 show some exposed loops including the MT-loop of cdMT3-MMP involved in the interaction with the proMMP-2 pro-domain in the activation encounter complex. This model might help to understand the experimentally proven importance of the MT-loop for the activation of proMMP-2.
INTRODUCTION
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases, which are capable of collectively degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. 1 The MMPs play an important role in tissue remodeling associated with various physiological and pathological processes such as morphogenesis, angiogenesis, tissue repair, arthritis and tumor invasion. [2] [3] [4] [5] [6] According to their cellular localization, the 23 human MMPs can be subdivided into 16 secreted and seven membrane bound MMPs. The latter MMPs include (i) the type-II transmembrane cysteine array MMP-23, 7, 8 (ii) the glycosyl phosphatidylinositol-attached MMPs 17 and 25/membrane-type MT-MMPs 4 and 6, 9,10 and (iii) the type-I transmembrane MMPs 14, 15, 16 , and 24/MT-MMPs 1, 2, 3, and 5. 11 In addition, some secreted MMPs such as (pro)MMP-2 are recruited to and activated at the cell surface to make focal proteolysis. 12 It has been proposed that this surface binding (e.g. via integrin interaction) might allow the fine control of ECM degradation near the cell surface of tumor cells. 13 On the other hand, the location of membrane-type MMPs at the plasma membrane situates them in a position suitable to promote tumor invasion.
The MT-MMPs 1, 2, 3 and 5 play a dual role in cell surface proteolysis, in that they are able to cleave a variety of extracellular matrix components in vitro and to shed membrane-bound receptors, 14 but are also capable of activating proMMP-2 (pro-gelatinase A).
11 MT1-MMP seems to be the major activator of proMMP-2, mainly via presentation of proMMP-2 by a MT1-MMP-TIMP-2 "receptor". [15] [16] [17] [18] However, the catalytic domains or the fulllength molecules of the other MT-MMPs [19] [20] [21] [22] [23] have also been shown in vitro or expressed in mammalian cells, respectively, to activate proMMP-2. Apparently, MT2-MMP is able to perform this activation in a TIMP-2-independent manner. 24 The proMMP-2 activation ability has been associated with a characteristic loop insertion (the MT-specific loop) 25 between strands sII and sIII of the catalytic domain, 26 and, accordingly, the inefficiency in proMMP-2 activation of the classical MMPs and MT-MMPs 4 27 and 6 28, 29 with the lack of this loop. The more severe phenotype exhibited by MT1-MMP knock-out mice compared with MMP-2 deficient mice 30, 31 indicates, however, that the MT-MMPs 1, 2, 3 and 5 play a much broader role than simply to activate proMMP-2. While MT-MMPs 1 and 2 are expressed in a variety of adult human tissues, expression of the MT-MMPs 3 and 5 seems to be restricted normally to the brain and the heart. 21, 32, 33 MT3-MMP, like MT1-MMP, is highly expressed in cancerous tissues compared with normal tissues. It has been found in renal carcinoma, 34 astrocytic tumors 33 and melanoma, 32 while it was not detected in breast and thyroid carcinomas, which expressed MT1-MMP 35 MT3-MMP has been shown to possess the potential to promote melanoma invasion by forming a complex with melanoma chondroitin sulfate proteoglycan, a cell surface proteoglycan expressed early in melanoma progression.
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MT3-MMP (originally described by Takino and co-workers 22 ), similar to the related MT-MMPs, is translated as a multidomain 607-residue polypeptide chain, consisting of a short signal peptide, a prodomain linked via a multiple basic furin cleavage site 37 with the catalytic domain, a long linker, a hemopexin-like domain, a transmembrane helix and a short cytoplasmic tail. Miyazaki and colleagues later published the slightly different cDNA sequence from human brain, which now seems to be generally accepted as the human MT3-MMP. 38 Besides, a soluble human MT3-MMP species formed by alternative splicing has been described. 39 MT3-MMP bears particularly strong sequence homology with MT5-MMPs. 21, 22, 38 Like MT1-MMP, it is inhibited by TIMP-2 but not by TIMP-1. 40 More efficiently than MT1-MMP does MT3-MMP digest type III collagen into typical one-and-three-quarter fragments, while it cleaves type I collagen only at the Gly4-Ile5 bond of the triple helical portion of the α2(I) chain. 40 Previously, we have determined the structure of the MT1-MMP catalytic domain in complex with TIMP-2 and found some characteristic differences such as the MT-specific loop compared with the classical MMPs. 25 Here we present the crystal structure of the related cdMT3-MMP in complex with the broad spectrum inhibitor batimastat. This structure hopefully will help in the rational design of more specific inhibitors, which might be useful for differentiating studies on the MT-MMPs.
RESULTS AND DISCUSSION

Overall structure
The MT3-MMP crystals contain one copy of the complex formed between the catalytic domain of MT3-MMP (cdMT3-MMP) and the hydroxamic acid inhibitor batimastat (BB-94) per asymmetric unit. The first five residues of this construct (Met1-Tyr120
MT3 -Thr123 MT3 ; the superindex MT3 indicates MT3 residues numbered according to proMT3-MMP; in the following paragraphs, the superindices pro2, MT1, MT2, Ml, M8, T1 and T2 will be used to refer to residues of proMMP-2, MT1-MMP, MT2-MMP, MMP-1, MMP-8, TIMP1 and TIMP-2, respectively) are not defined by electron density, although there is enough empty space in the crystal to accommodate it in an unconstrained manner. This indicates that the Tyr120 MT3 α-amino terminus of mature MT3-MMP (and thus, in general, the amino termini of the MT-MMPs) is inherently flexible and not involved in a surface-located salt bridge with Asp281 MT3 as observed in the collagenases, 41 which is probably due to the two residues shorter amino terminus of activated MT-MMPs (Figure 1(d) ) or the presence of the artificial methionine of our construct. Also the last 15 amino acid residues of this construct, which in the fulllength molecule would represent part of the 50-residue inter-domain linker, are not defined by electron density.
As in other MMPs, the MT3-MMP active-site cleft, which in the standard orientation ( Figure 1 ) extends horizontally across the molecule and binds peptide substrates from left to right, separates the smaller "lower subdomain" from the larger "upper subdomain". The upper subdomain encompasses a five-stranded, highly twisted β-sheet, flanked by three surface loops on its convex side and by two long regular α-helices on its concave side (Figure 1(a) ). Four of the five β-strands are aligned in a parallel fashion, with only the cleft-sided "edge strand" sIV running in opposite direction. This latter strand is linked to the central strand sIII via the characteristic "S-shaped double loop" (S-loop), which is fixed via the "structural zinc" (Zn2, Figure 1 (a)) and the first bound calcium ion (Ca1) to the underlying β-sheet. This S-loop extends into the cleft-sided "bulge", which continues into the antiparallel edge sIV, both together forming the alignment segment for binding peptidic substrates and inhibitors (see Figures 1 and 2 ). The end of the sII-sIII connecting segment, also called MT-loop due to its unique presence in MT-MMPs (see below), together with the sIV-sV loop sandwich the second calcium ion (Ca2).
After strand sV, the chain passes through the large open sV-hB loop, another segment of high variability ( Figure  1(a) ) and a source of specificity 42 before entering the long horizontally extending "active-site helix" hB. This helix provides the first and the second His residue of the metzincin 43 characteristic zinc-binding motif (His246 MT3 and His250 MT3 , using the proenzyme numbering of MT3-MMP, together with the "catalytic" Glu247
MT3 ; see Figure 1 , differs only by a Ser/Thr replacement. Therefore, MT3-MMP might show a similar preference for Arg residues at P4 in the absence of P3-Pro residues. 46 The hydrophobic S2 subsite is bordered by Glu255
MT3
, so that its shallow groove could particularly well accommodate short hydrophobic side-chains (such as Cys, see below), but also Arg/Lys at P2; the corresponding Glu248 MT1 sidechain of MT1-MMP (see Figure 2) turns away from the S2 subsite, probably due to the presence of the amino terminus of the MT1-MMP catalytic domain co-crystallized with TIMP-2. 25 The S1 cleft of MT3-MMP is, as that of MT1-MMP, bounded by the flat sides of the side-chains of His208 MT3 (one of the ligands of the structural zinc) and Phe205 MT3 (Figure 2 ), distinguishing it from the S1 sites of most other MMPs. The catalytic zinc ion is partially exposed (central pink sphere). The bound batimastat inhibitor of cdMT3-MMP is shown with atom colors (green carbon atoms), while the bound TIMP-2 is removed from the cdMT1-MMP/TIMP-2 complex. 25 In contrast to the continuous S1' tube (to the right of the catalytic zinc, (c)) of MT1-MMP, the S1' specificity pocket of cdMT3-MMP is blocked. Figures were made with Swiss PDBViewer 75 and PoV-Ray /MegaPov.
The entrance to the S1' subsite is mostly hydrophobic as in the other MMPs. In contrast to the MT1-MMP, however, the MT3-MMP S1'-subsite is not a continuous pore but a limited pocket, bounded at its bottom by the Met271 MT3 side-chain, which in turn seems to be squeezed between the side-chains of Ile263 MT3 and Gln269
.
The equivalent Met264
MT1 side-chain of MT1-MMP, packed between similar neighbors, is rotated out of the pocket and gives way to the S1' pore, possibly due to lack of a laterally stabilizing Tyr270 MT3 -Asn234 MT3 sidechain stack as found in MT3-MMP This S1' difference is also reflected in main-chain deviations of the embracing specificity loop (Figure 1) . We note that the equivalent Arg222 M8 side-chain of MMP-8 44 secludes the S1' pocket in a similar manner as observed in MT3-MMP However, a recent MMP-1/inhibitor structure shows that long side-chains in S1' are able to displace the occluding Arg214 M1 in MMP-1. 47 Such flexibility in pocket size may also be assumed for MT3-MMP.
The S2' subsite is bordered by the protruding benzyl side-chain of Phe205 MT3 and the integrated benzyl group of Phe267 MT3 , provided by the bulge-edge segment and by the S1' wall forming segment (see Figure 2 (a) and (b)). The S2' groove of MT1-MMP, with identical residues, is very similar. With the exception of MT4-MMP, both Phe residues are conserved among the MT-MMPs, but are replaced by medium-sized and/or more polar residues in the classical MMPs. Thus, the inability of MT3-MMP to cleave, like MT1-MMP, collagen type I into threequarter and one-quarter fragments cannot be explained by significant structural differences in the active site cleft, but must rather reside in different exosite interactions, or result from a combination of multiple subtle contacts.
The bound batimastat inhibitor is well defined by appropriate electron density (Figure 2(a) ). It coordinates the catalytic zinc ion in a bidentate manner via the hydroxyl (distance 2.24 Ǻ) and the carbonyl oxygen (distance 1.87 Ǻ) of the hydroxamic group. Both oxygen atoms, together with the three ligating His nitrogen atoms (Zn distances between 2.02 and 2.16 Ǻ), make up a trigonal-bipyramidal coordination sphere around this zinc ion. The peptide-like backbone is bound similar to that observed in the corresponding batimastat complex with MMP-8, 48 i.e. inserted between the bulge-edge strand and the wall-forming segment, under formation of five inter-main-chain hydrogen bonds (distances between 2.79 and 2.98 Ǻ). The thiophene ring, in α-position to the hydroxamate moiety, is located above the catalytic zinc, but at a mean distance of 4.5 Ǻ, i.e. too far away for a favorable half-sandwich complex. The isopropyl group of batimastat, mimicking a P1' "Leu" side-chain, extends into the S1' pocket, still leaving space for a few more solvent molecules. The P2' phenyl ring forms both intra-(with the thiophene ring) as well as intermolecular contacts (with Phe205 MT3 and Phe267 MT3 ), giving rise to a smooth surface spanning the primed region of the cleft.
The MT-specific loop and its possible involvement in proMMP-2 activation MT3-MMP shares with MT1-MMP (and probably with MT2-and MT5-MMP) the characteristic MT-loop that connects strands sII and sIII and forms a dominating protuberance on the molecular surface (see Figure 1) . Here, 14 residues of the MT3-MMP chain between Glu168 MT3 and Asp183 MT3 replace seven residues in the "classic" MMPs ( Figure 1(d) ) and the non-activating MT4-MMP, and ten residues in MT6-MMP The corresponding loop of MT5-MMP is of identical length, whereas the MT-loops of MT1-and MT2-MMP are one residue longer and (in the middle part) of different sequence. According to mutation/ deletion/kinetic experiments of Murphy and coworkers, 26 the second half of the equivalent MT-loop of MT1-MMP is not particularly important, whereas the specifically structured N-terminal part seems to be required for efficient activation of proMMP-2. , due to an extra bulge at Val162 MT1 and differing intramolecular packing. It should be mentioned that in both, the MT1-MMP-TIMP-2 structure 25 as well as in this MT3-MMP-batimastat structure, the MT-loop protrudes into empty intermolecular gaps, relatively unconstrained by crystal contacts. The cdMT2-MMP from man has been shown to activate proMMP-2, 24 and human and mouse MT2-MMPs expressed in COS cells were reported to be active. 49 The same group in a later study found, however, that human MT2-MMP is defective, but that the cell-associated proMMP-2 activation function can be recovered by replacement of the human Glu181 MT2 -Val182
It is thus peculiar that just the N-terminal part of the MT3-MMP loop (
MT2 motif. 50 According to Tyr MT1 → Ser mutation experiments of English and colleagues, 26 the contained Tyr MT1 residue seems to play some role in the proMMP-2 activation, possibly acting as a molecular switch upon docking to proMMP-2. The different phenole placement in the MT1-and the MT3-MMP structures does not explain such a function, however, indicating that the mechanism of the MT-loop involvement in proMMP-2 activation is more complex.
The strong correlation of the presence of the MT-loop with the capability of activating proMMP-2, but also the mutation experiments mentioned above 26 suggest a (direct or indirect) involvement of the MT-loop in proMMP-2 activation. The MT1-MMP catalyzed proMMP-2 activation starts with a cleavage in the Glu63 pro2 -Ser64 pro2 -Cys65 pro2 -Asn66 pro2* Leu67 pro2 -Phe68 pro2 segment of proMMP-2, i.e. in the loop connecting helices 1 and 2 of the prodomain. 51 The activation intermediate is then further processed and the final cleavage at Asn109 pro2 -Tyr110 pro2 through another MMP-2 molecule yields active MMP-2. 17, 52, 53 In both proMMP-2 structures 51,54 the primary cleavage segment is in a position and conformation not accessible for an attacking MT1-MMP, and the residues flanking the primary cleavage site, in particular those C-terminal of it, exhibit enormously high temperature factors. This indicates that the cleavage segment is quite flexible and can adapt to an attacking MT-MMP molecule. Modeling studies show that the primed side segment must partially unfold up to Lys75 pro2 and adopt an MT-MMP-susceptible conformation 55 (see model in Figure 1 (b) and (c)), while the relatively rigid nonprimed side Cys60 pro2 -Cys65 pro2 loop must slightly rearrange in order to become attackable by the approaching MT-MMP 56 Manual docking experiments show that a refolded scissile proMMP-2 segment could insert into the active-site cleft of MT1/3-MMP in a productive manner, under simultaneous touch of helix 2 by the S-loop, insertion of the end of helix 1 below the S-loop, and contacts between the MMP-2 segment becoming the N terminus and the MT-loop (Figure 3(a) ). In this way, the MT-loop could directly or indirectly stabilize the encounter complex facilitating proMMP-2 activation. Also other encounter complexes are conceivable, however, e.g. under association of both hemopexin-like domains. 57 Interestingly, a hemopexin-like domain-dependent activation has been described for the MT2-MMP-dependent activation of proMMP-2 24 and the MT1-MMPdependent activation of proMMP-13.
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TIMP-1 docking to MT-MMPs shows obstacles for interaction
Previously we have shown for a cdMMP-3-TIMP-1 59 and for a cdMT1-MMP-TIMP-2 complex 25 that the wedgeshaped TIMPs bind with their flexible edge consisting of six loops/segments into the entire active-site cleft of their cognate MMPs. The TIMPs mainly interact through their N-term-inal segment and the disulfide connected C-D loop, but make a number of contacts through the peripheral sA-sB loop and the two C-terminal loops. A superposition of both experimental complexes on the basis of the cdMMPs shows that the relative orientations of both cdMMPs and TIMPs differ considerably, what seems to be an inherent, characteristic difference between both TIMPs (Figure 3(a) ). As a consequence, the C-terminal Cys132 T1 -Cys137
T1 loop of TIMP-1 gets much closer to the sV-hB loop of the cognate MMP. In all MT-MMPs, the sV-hB loop is, however, longer for three residues (Figure 1(d) ) and bulges out toward the approaching TIMP (see Figure 3(a) ). Docking studies with TIMP-1 and MT3-MMP show that in particular Asn234 MT3 and His235 MT3 would clash with Leu133 T1 and Ser134
T1
. Favorable interactions here would require conformational adaptations, presumably on the cost of free energy of binding.
On the other hand, the favorable hydrophobic contacts between the TIMP-2 patch formed by Ile157 T2 and Trp151 T2 with Phe260 MT1 (Phe267 MT3 ) would not be possible with TIMP-1 (Figure 3(b) ). In our modeled TIMP-1-MT3-MMP complex, only the hydrophobic part of the Glu156 T1 side-chain would get into contact with Phe267 MT3 (Phe is conserved in all human MT-MMPs except for MT4-MMP, where it is a Tyr). Furthermore, an MT1/3-MMP complex with TIMP-1 would lack the favorable interactions made by the extended sA-sB loop of TIMP-2, which in the MT1-MMP-TIMP-2 complex slots into the surface groove left by the MT-loop, the sidechains of Asp212 MT1 and Phe250
MT1
, and the S-loop of MT1-MMP 25 The importance of these interactions for the MT-MMP-TIMP-2 complex stability is shown by the 40-fold reduction in the apparent Ki value of the Tyr36 T2 Gly sA-sB loop tip mutants (of N-TIMP-2) for association with MT1-MMP 18 These interactions mediated through the sA-sB loop might also pull the "left" side of TIMP-2 (Figure 3(a) ) towards the MT1-MMP molecule, thus preventing the approach of the "right" side, which in the modeled TIMP-1 complex shows clashes (see above). In summary, the crystal structures of MT1-and MT3-MMP are not in agreement with the favorable binding of TIMP-1, somewhat explaining the extremely low association reaction/affinity.
When we had completed this manuscript, we became aware of a new paper describing a triple mutant rendering TIMP-1 as active against MT1-MMP as other TIMPs. 60 The critical replacement is that of Thr98
T1
, which in our model faces a solvent-exposed cavity formed by the molecular MT1/3-MMP-TIMP-1 interface and just touches the side-chains of Pro266 MT3 and Phe267 MT3 (see Figure 3(b) ), by Leu98
. In essence, the longer leucine sidechain in this position may interact more intimately with Pro266 MT3 and may also touch His256 MT3 and Phe267 MT3 , thus forming a much better hydrophobic interaction with MT1/ 3-MMP Interestingly, Thr98
, which is located in the E-F loop of TIMP-1, is (because of the different loop conformation, but also due to different chain lengths) topologically equivalent to Leu100 T2 (Figure 3(b) ). 25 This makes the favorable effect of the Thr → Leu replacement somewhat conceivable, but not its extent. The multiple contacts of the inherently flexible TIMP loops make the assessment of replacement effects extremely difficult.
This mutant is remarkable in that it shows that small apparently insignificant changes in the TIMPs can shift the inhibitory answer from "no" to "yes". 
MATERIALS AND METHODS
Cloning, expression, refolding and purification of cdMT3-MMP
For the PCR amplification of the cDNA encoding cdMT3-MMP (from nucleotide 470 to nucleotide 1042), the MT3-MMP plasmid, kindly provided by H. Sato, was used as a template together with two synthetic nucleotide primers designed according to the known cDNA sequence (Accession number D50477). 22 The sense primer 5'-GGAATTCATATGTATGCATTGAC AGGACAGAA-3' and the antisense primer 5'-AA CTGCAGCTAGCGGTGTGG GGGCACTGT-3' were designed to incorporate Nde I or Pst I sites (underlined) and an N-terminal methionine, respectively. The amplified PCR fragment was digested with these restriction enzymes and cloned into the pCTBR2 vector. 61 The resulting plasmid was called pT7cdMT3.
BL21 (DE3) cells were transformed with the pT7cdMT3 plasmid and grown as described. 62 The cdMT3 expression was induced by adding 0.5 mM iso-propyl-β-D-galactopyranoside for three hours when the cell density reached an A 600 of 0.6. The cells were harvested by centrifugation and resuspended in lysis buffer (50 mM Tris-HCl (pH 7.5), 100 KCl, 0.1% Brij). The lysate was sonicated and the inclusion bodies were collected by centrifugation, and washed three times each with 50 mM Tris-HCl (pH 7.5), 2 M NaCl, 0.1% Brij, and with 50 mM Tris-HCl (pH 7.5).
Washed inclusion bodies were solubilized by stirring for two hours at 22°C in 50 mM Tris-HCl (pH 8.5), 8 M urea, and 0.1% β-mercaptoethanol. The denaturation mixture was dialyzed for four hours each at 4°C against a 50mM Tris-HCl (pH 8.5) buffer containing 100 mM NaCl, 10 mM CaCl 2 , 100 µM ZnCl 2 , and urea at progressively decreasing concentrations in order to slowly eliminate urea. Additional dialyses were performed for 24 hours against Tris assay buffer (50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM CaCl 2 , 1 µM ZnCl 2 ). The refolded cdMT3 (with residues Metl-Tyrl20
38 was concentrated by ultra-filtration (3-kDa cutoff, YM3 membrane, Amicon), and the precipitate was removed by centrifugation after incubation overnight at 4°C. The supernatant was subjected to a HitrapQ anion-exchange column (5 ml, Pharmacia) equilibrated with 50 mM Tris-HCl (pH 7.5) and 5 mM CaCl 2 , and eluted with a NaCl gradient (0-500 mM) in 50 mM Tris-HCl (pH 7.5), and the peak fractions containing the homogenous cdMT3 were pooled.
Crystallization, data collection, and structure refinement
The human cdMT3-MMP-batimastat complex was crystallized using the sitting-drop vapor-diffusion technique. An aliquot of 1 µl protein/inhibitor solution (50 mM Tris-HCl (pH 8.5), 100 mM NaCl, 5 mM CaCl 2 , containing 10 mg/ml cdMT3-MMP and 0.5 mg/ml batimastat) was mixed with 1 µl reservoir buffer (100 mM Tris-HCl (pH 8.7), 1.1 M K/Na-tartrate) and concentrated against the reservoir at room temperature. Batimastat/ BB-94, a broad spectrum MMP-inhibitor with a Ki for MMP-1, -2 and -3 of about 1 nM, 63 was a generous gift from British Biotech. After a few days, brick-like crystals (200 µm X 200 µm X 100 µm) formed belonging to the tetragonal space group P4 3 22 (Table 1) . With one monomer of 21.3 kDa per asymmetric unit, these crystals have a solvent content of 47% (v/v).
After adding 20% (v/v) glycerol to the mother liquor, a first data set to 2.2 A resolution was collected from a crystal cooled to 100 K in a nitrogen stream on a MAR-Research (Hamburg, Germany) 345 image plate detector by using monochromatized CuK α radiation produced by a conventional rotating anode. The data set was processed with the HKL package. 64 The orientation and position of the human cdMT3-MMP-batimastat complex was determined by Patterson search techniques using the program AMoRe 65 and the catalytic domain of human MT1-MMP (PDB accession code 1BQQ; residues: Πell4-Ser287) 25 as a search model. A second dataset to 1.80 A resolution was collected with a flash-cryocooled crystal at a wavelength of 1.050 A at the beamline BW6 of the Deutsches Elektronen Synchrotron (DESY) in Hamburg, Germany, employing a Mar Research CCD detector. The structure of the human cdMT3/batimastat complex was refined with XPLOR 66 using the Engh & Huber parameters. 67 The Rf ree validation was based on a subset of 4.9% of the reflections omitted during the entire refinement procedure. In later stages of refinement, the maximum-likelihood algorithm implemented in the program CNS 68 was used. Each round of refinement was followed by manual model rebuilding using the programs O 69 and MAIN. -Asp236 MT3 , the cdMT3-MMP main-chain can be fully traced in continuous electron density. All main-chain angles of non-glycine residues fall into the most favored or allowed regions of the Ramachandran plot as defined by PROCHECK.
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Protein Data Bank accession code
The structure of the cdMT3-MMP/batimastat complex reported here has been deposited in the RCSB Protein Data Bank (PDB code: 1RM8).
